Cynata Therapeutics Ltd has released a press release.
Ethics Approval & Expedited Pathway for Phase 3 OA Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Block Trade Proceeds to Reduce Director Loans
- Cynata Successfully Completes Share Purchase Plan
- Ethics Approval to Commence Clinical Trial in COVID-19
- Share Purchase Plan Booklet
- Cynata announces $5.55m capital raising
Later from Cynata Therapeutics
- Cynata Announces Positive Results from GvHD Trial Follow-up
- Cynata Appoints Dr Geoff Brooke as Chairman
- Patient Enrolment Opens in COVID-19 Clinical Trial
- Cymerus MSCs Effective in Preclinical Lung Disease Study
- Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics